Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.3 - APH LN

14 Jan 2025 15:00

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Sand Grove Capital Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Fund(s) for which Sand Grove Capital Management LLP serves as the Investment Manager or Discretionary Sub-Advisor

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Alliance Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

13 January 2024

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ordinary

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

12,312,879

2.28%

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

12,312,879

2.28%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

1p ordinary

Purchase

1,100,000

61.15p

1p ordinary

Purchase

3,800,000

61.1p

1p ordinary

Purchase

1,200,000

61.15p

1p ordinary

Purchase

1,800,000

61.1p

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:

14 January 2024

Contact name:

James Evans

Telephone number:

+44 203 161 0743

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114766379/en/

Copyright Business Wire 2025

Date   Source Headline
23rd Nov 20165:45 pmRNSExercise of Share Options
17th Nov 20165:05 pmRNSNotification of Major Interest in Shares
17th Nov 201610:40 amRNSExercise of Share Options
28th Oct 20165:13 pmRNSShare Options
28th Oct 20167:00 amRNSAppointment of Deputy CEO
5th Oct 20166:00 pmRNSExercise of Share Options
23rd Sep 20167:01 amRNSExercise of Share Options
23rd Sep 20167:00 amRNSDirector Dealings
14th Sep 20167:00 amRNSInterim Results
13th Sep 20167:00 amRNSNew Agreement for Diclectin in Europe
18th Aug 20167:00 amRNSInterim Results Analyst Meeting - Change of Time
8th Aug 20165:00 pmRNSExercise of Share Options
2nd Aug 20167:00 amRNSNotification of Interim Results
26th Jul 20167:00 amRNSExercise of Share Options
19th Jul 20167:00 amRNSHalf Year Trading Update
12th Jul 20167:00 amRNSNotification of Half Year Trading Update
25th May 201611:15 amRNSResult of AGM
25th May 20167:00 amRNSAGM Statement
24th May 20167:00 amRNSExercise of Share Options
5th May 20161:30 pmRNSDirector Shareholding
3rd May 20167:00 amRNSExercise of Share Options
28th Apr 20167:00 amRNSAnnual Report and AGM Notice
7th Apr 20167:00 amRNSPreliminary Results
18th Mar 20167:00 amRNSNotification of Preliminary Results
3rd Mar 20167:00 amRNSHardman & Co Research Report
5th Feb 20163:57 pmRNSExercise of Share Options
22nd Jan 20163:45 pmRNSExercise of Share Options
21st Jan 20167:00 amRNSPre-Close Trading Update
12th Jan 20162:34 pmRNSNotification of Major Interest in Shares
7th Jan 20161:56 pmRNSNotification of Major Interest in Shares
23rd Dec 201512:02 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
22nd Dec 20154:40 pmRNSDirector Shareholding
18th Dec 20155:15 pmRNSNotification of Major Interest in Shares
18th Dec 20154:20 pmRNSNotification of Major Interest in Shares
18th Dec 20153:54 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th Dec 20153:39 pmRNSNotification of Major Interest in Shares
17th Dec 20153:13 pmRNSNotification of Major Interest in Shares
17th Dec 20159:00 amRNSCompletion of Acquisition and Placing
14th Dec 20154:00 pmRNSResult of General Meeting
8th Dec 20155:41 pmRNSNotification of Major Interest in Shares
7th Dec 20157:00 amRNSShare Options
3rd Dec 20152:03 pmRNSPlacing Update: Exercise of Broker's Option
2nd Dec 20158:00 amRNSSchedule 1 - Alliance Pharma Plc
26th Nov 20154:35 pmRNSInterim Dividend Timetable
26th Nov 20157:00 amRNSProposed Acquisition
23rd Nov 20154:00 pmRNSDirectorate Change
5th Nov 20157:00 amRNSSettlement Agreement
10th Sep 20157:00 amRNSInterim Dividend Timetable - Record Date
9th Sep 20157:00 amRNSInterim Results
2nd Sep 20156:01 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.